SOURCE: NeuroInvestment

July 10, 2006 13:12 ET

CNS Sector MidYear Review From NeuroInvestment

CARDIFF, CA -- (MARKET WIRE) -- July 10, 2006 -- NeuroInvestment today announced the release of its July issue, which reviews the status and events of the CNS therapeutics area during the first half of 2006 -- for both public and privately held companies.

1H:06 was a tale of two quarters, with a positive 1Q (the NI Index was up 7.17%) followed by one of the worst quarters we have seen in our eleven year history, the NI Index plummeting 31%. The abrupt turnaround in the fortunes of Neurocrine Biosciences (NASDAQ: NBIX) and Dov Pharmaceuticals epitomized this reversal, and the July issue's article entitled 'The Search for Intelligent Life on the Planet Indiplon' further updates the prospects for that insomnia drug.

It was not as if the first half was bereft of positive developments. Elan and Biogen-Idec's Tysabri received its go-ahead from the FDA; Cephalon successfully defused the generic threats to its Provigil franchise; CX717 from Cortex (AMEX: COR) performed surprisingly well in an ADHD trial; Pfizer bought Rinat Neuroscience for a record-breaking sum; Neuromed's lead analgesia program was partnered by Merck; and Torrey Pines Therapeutics came to the rescue of Axonyx.

The MidYear Review also takes a look at the abuse liability data for New River's NRP104; the errant pursuit of full vertical integration by small companies responding to the siren's song of co-promotion; and Neurocrine's valuation in the aftermath of Pfizer dropping the indiplon partnership. The second half of 2006 will see critical events for Cortex, Acorda (NASDAQ: ACOR), Corcept, Acadia, Renovis (NASDAQ: RNVS), New River, Addex, Predix, and D-Pharm. It might also see Big Pharma finally making effective use of its billions in repatriated cash as the merger and acquisition flow increases.

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995, the Private CNS Company Review since 2003, and provides strategic development consultation and custom research for pharmaceutical firms. NI Research has developed an unmatched information base regarding publicly and privately-held neuro-oriented companies.

Subscription Rates: One-year corporate subscription to NeuroInvestment is $1400, email or hardcopy. Add $150 for dual delivery, add $40 for airmail delivery outside North America. A three month trial subscription is US$450. Individual investor subscriptions are $450 for one year, $150 for a three month trial.

Contact Information

  • Contact:
    Dr. Harry M. Tracy
    NI Research, P.O. Box 1028
    Cardiff, CA 92007
    E-mail: Email Contact